Registry for patients with lymphoid cancers
Bergamo Lymphoid Cancer Registry
This study is collecting information from patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma to better understand their conditions and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | A.O. Ospedale Papa Giovanni XXIII Academic / other |
| Locations | 1 site (Bergamo) |
| Trial ID | NCT03131531 on ClinicalTrials.gov |
What this trial studies
This registry aims to enhance understanding of the clinical and biological characteristics of patients diagnosed with Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. By collecting clinical data through validated electronic charts and biological specimens, the study seeks to address issues such as treatment refractoriness and disease recurrence in a real-world setting. The data gathered will allow for analysis of treatment practices and facilitate biological studies that could have significant implications for clinical practice.
Who should consider this trial
Good fit: Ideal candidates include male and female patients aged 18 years or older with a confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas, or myeloma.
Not a fit: Patients with an unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas, or myeloma will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with lymphoid cancers.
How similar studies have performed: Other studies focusing on patient registries for hematologic malignancies have shown success in improving understanding and treatment outcomes, indicating that this approach is both relevant and beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patients 18 years or older * Written informed consent * Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma Exclusion Criteria: \- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Where this trial is running
Bergamo
- Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII — Bergamo, Italy (Recruiting)
Study contacts
- Principal investigator: Alessandro Rambaldi, MD — A.O. Ospedale Papa Giovanni XXIII
- Study coordinator: Alessandro Rambaldi, MD
- Email: arambaldi@asst-pg23.it
- Phone: +39.035.2673683
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.